glp-1 gastroparesis class action in kentucky lawyer Ozempic Lawsuit for Gastroparesis glp-1 gi obstruction lawyer in
Description
In the STEP 1 trial, 86% of participants lost at least 5% of their body weight, and 50% lost 15% or more
These findings highlight the importance of maintaining continuous GLP-1 treatment to sustain cardiovascular benefits and indicate that strategies to reduce treatment discontinuity should be developed to maximize the cardioprotective effects of GLP-1s
Persons under consideration must NOT have a prior diagnosis or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2)
mediation analyses suggest part of the effect is independent of weight/HbA1c
